Darrell Tan




Dr. Darrell Tan is an infectious diseases physician, clinician-scientist and Canadian Institutes of Health Research (CIHR) New Investigator whose research focuses on clinical trials in human immunodeficiency virus (HIV) prevention and HIV/sexual transmitted infection (STI) co-infection. As Director of the University of Toronto Clinical Research Unit on HIV Prevention and co-leader of the CIHR Canadian HIV Trials Network Biomedical Prevention Working Group, he is leading multiple efforts to optimize the implementation of HIV pre- and post-exposure prophylaxis (PrEP and PEP) in Canada. These include Canada’s first demonstration project of daily oral TDF/FTC-based PrEP in Toronto MSM, the development of national Clinical Practice Guidelines on PEP & PrEP use, exploration of the relationship between syndemic health problems and clinical outcomes of PEP & PrEP, studies of nurse-led PEP & PrEP, and evaluations of novel antiretroviral PEP regimens.

Additional research interests are in the interaction between HIV and common co-infections such as herpes simplex virus type 2 (HSV-2) and syphilis, and the role of systemic inflammation in driving clinical outcomes in people living with HIV. He is also Co-Principle Investigator on two CIHR-supported multicentre randomized control trials including the a trial of anti-herpes medication for attenuating HIV disease progression, and a trial of enhanced syphilis screening in HIV-positive men.

Recent Publications

  1. Cheng, MP, Lee, TC, Tan, DHS, Murthy, S. CMAJ. 2020;192 (42):E1296-E1298. doi: 10.1503/cmaj.200438-f. PubMed PMID:33077531 PubMed Central PMC7588204.
  2. Rana, J, Guiang, CB, Lisk, R, Shahin, R, Brunetta, J, Mitterni, L et al.. Survey of Health Care Providers' Practices and Opinions Regarding Bacterial Sexually Transmitted Infection Testing Among Gay, Bisexual, and Other Men Who Have Sex With Men. Sex Transm Dis. 2021;48 (2):94-102. doi: 10.1097/OLQ.0000000000001287. PubMed PMID:33003183 .
  3. Tan, DHS, Agrawal, R, Barnabas, RV, Giles, JT, Dull, P. Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis. Trials. 2020;21 (1):815. doi: 10.1186/s13063-020-04754-9. PubMed PMID:32993804 PubMed Central PMC7523255.
  4. Wright, JK, Tan, DHS, Walmsley, SL, Hulme, J, O'Connor, E, Snider, C et al.. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. Trials. 2020;21 (1):647. doi: 10.1186/s13063-020-04577-8. PubMed PMID:32665039 PubMed Central PMC7359423.
  5. Tan, DHS, Dashwood, TM, Wilton, J, Kroch, A, Gomes, T, Martins, D et al.. Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018). Can J Public Health. 2020; :. doi: 10.17269/s41997-020-00332-3. PubMed PMID:32529552 .
  6. Clifford-Rashotte, M, Fawcett, N, Fowler, B, Reinhart, J, Tan, DHS. Assessing the Potential for Nurse-Led HIV Pre- and Postexposure Prophylaxis in Ontario. Can J Nurs Res. 2020; :844562120924269. doi: 10.1177/0844562120924269. PubMed PMID:32380845 .
  7. Cheng, MP, Lee, TC, Tan, DHS, Murthy, S. Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. CMAJ. 2020;192 (15):E405-E407. doi: 10.1503/cmaj.200438. PubMed PMID:32336678 PubMed Central PMC7162442.
  8. Wang, L, Tan, DHS, Mishra, S. Evidence of Nonrandom Mixing by Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men Partnerships in Melbourne, 2016 to 2018. J Acquir Immune Defic Syndr. 2020;84 (4):e22-e23. doi: 10.1097/QAI.0000000000002387. PubMed PMID:32332422 PubMed Central PMC7340229.
  9. Strike, C, Robinson, S, Guta, A, Tan, DH, O'Leary, B, Cooper, C et al.. Illicit drug use while admitted to hospital: Patient and health care provider perspectives. PLoS One. 2020;15 (3):e0229713. doi: 10.1371/journal.pone.0229713. PubMed PMID:32134973 PubMed Central PMC7058273.
  10. Tan, DHS, Lee, T, Raboud, J, Qamar, A, Cheung, AM, Walmsley, S et al.. Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial. HIV Res Clin Pract. 2019;20 (6):140-150. doi: 10.1080/25787489.2020.1730114. PubMed PMID:32106792 .
Search PubMed

Affiliations & Other Activities

  • Clinician-Scientist, Department of Medicine, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, University of Toronto
  • Assistant Professor, Institute of Health Policy, Management & Evaluation, University of Toronto
  • Director, HIV Prevention Clinical Research Unit, University of Toronto
  • Affiliate Scientist, Toronto General Research Institute